1173976-40-3 Usage
Uses
Used in Pharmaceutical Industry:
Gefitinib O-Methyl-D3 is used as a labeled compound for the development and study of targeted cancer therapies. Its light-yellow crystalline powder form allows for easy incorporation into pharmaceutical formulations and research protocols.
Used in Cancer Research:
Gefitinib O-Methyl-D3 is used as a research tool for understanding the mechanisms of action and resistance to EGFR inhibitors in cancer cells. Its labeled nature enables researchers to track and monitor the compound's interactions with cellular targets, providing valuable insights into the development of more effective cancer treatments.
Used in Drug Development:
Gefitinib O-Methyl-D3 is used as a reference compound in the development of new antineoplastic agents. Its structural similarity to Gefitinib allows researchers to compare and contrast the properties of new compounds, potentially leading to the discovery of more potent and selective cancer therapies.
Used in Quality Control:
Gefitinib O-Methyl-D3 is used as a quality control standard for the assessment of the purity and potency of Gefitinib in pharmaceutical products. Its labeled nature ensures accurate measurement and comparison, helping to maintain the safety and efficacy of cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1173976-40-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,3,9,7 and 6 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1173976-40:
(9*1)+(8*1)+(7*7)+(6*3)+(5*9)+(4*7)+(3*6)+(2*4)+(1*0)=183
183 % 10 = 3
So 1173976-40-3 is a valid CAS Registry Number.
1173976-40-3Relevant academic research and scientific papers
Derivatives of gefitinib
-
, (2016/03/12)
This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases.
